ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $1,316,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total value of $1,316,000.00. Following the completion of the transaction, the insider now owns 1,148,499 shares in the company, valued at $15,114,246.84. The trade was a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $14.88, for a total value of $1,488,000.00.

ARS Pharmaceuticals Stock Performance

NASDAQ:SPRY traded down $0.68 during mid-day trading on Wednesday, hitting $12.27. The stock had a trading volume of 1,445,428 shares, compared to its average volume of 821,057. The company’s 50 day simple moving average is $14.74 and its 200 day simple moving average is $12.32. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -25.39 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a twelve month low of $5.01 and a twelve month high of $18.51.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SPRY. Leerink Partners upped their price objective on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, September 20th. William Blair raised ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $18.00 to $22.00 in a research report on Tuesday, August 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $24.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of ARS Pharmaceuticals in the third quarter worth $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after purchasing an additional 4,472 shares during the last quarter. Principal Financial Group Inc. bought a new position in shares of ARS Pharmaceuticals in the 2nd quarter worth about $87,000. J.W. Cole Advisors Inc. boosted its holdings in shares of ARS Pharmaceuticals by 10.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after buying an additional 1,500 shares in the last quarter. Finally, Quarry LP bought a new position in ARS Pharmaceuticals during the third quarter worth $174,000. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.